Gilead Keeps on Building

One more step towards Gilead's HIV treatment empire.

Dave Williamson
Dave Williamson
Mar 22, 2013 at 9:02PM
Health Care

In the following video, Motley Fool health-care analyst David Williamson discusses a new E.U. approval for Gilead (NASDAQ:GILD) for its quad pill HIV drug cocktail, which has shares up 2% to near all-time highs. David tells investors why this is just one more piece to the puzzle for Gilead, as it continues to build its empire in the treatment of HIV.